From Name:
From Email:
To Name:
To Email:

Optional Message:


Stony Brook, Artelo Biosciences Announce License Agreement for Portfolio of FABP Inhibitor Drug Candidates

from The Virginian-Pilot

Artelo Biosciences, Inc., a biopharmaceutical company focused on the development of therapeutic treatments that modulate the endocannabinoid system, and The Research Foundation For The State University of New York, a not-for-profit organization and the largest comprehensive university-connected research foundation in the United States, has announced they have entered into a license agreement. Under the agreement, Artelo obtains an exclusive worldwide license to an intellectual property portfolio of Fatty Acid Binding Protein (FABP) inhibitor drug candidates, which have multiple potential indications, including cancer, inflammation and pain.

During the first year of the agreement, Artelo will collaborate closely with the Stony Brook University team that developed the technology to identify a lead development compound, develop a pharmaceutically acceptable formulation, and evaluate activity in nonclinical animal models across select indications. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063